Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More